Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

FY22 update: Sonic (ASX:SHL) share price keeps rising

The Sonic Healthcare Ltd (ASX:SHL) share price is going up after providing a positive trading update for FY22 at its AGM.

The Sonic Healthcare Ltd (ASX: SHL) share price is going up after providing a positive trading update for FY22 at its AGM.

Sonic Healthcare is one of the world’s largest pathology businesses. It has operations in ANZ, Europe and North America. It has been providing the essential service of COVID-19 testing since the pandemic began.

Sonic Healthcare’s FY22 update

The large healthcare business said that it continues to support governments, healthcare authorities and communities with COVID-19 initiatives.

Sonic’s laboratories are testing tens of thousands of people every day for COVID-19, with 36 million PCR tests in total to date, as well as conducting COVID-19 serology testing and, in some markets, COVID-19 whole genome sequencing to aid identification of variants.

In Australia, it has provided more than 1 million COVID-19 vaccinations to the community through special purpose high volume hubs and through its network of more than 200 medical centres.

But apart from that, Sonic’s non-COVID businesses continue to provide services.

Financial growth

Sonic reported that in the first four months of FY21, its revenue grew by 5% to $3.09 billion and its EBITDA (EBITDA explained) increased by 16% to $991 million.

The base business revenue, excluding COVID related services, grew by 6% year on year and it was up 4% against the same period in FY20 (before the pandemic). Those comparative periods were ‘normalised’ for currency exchange rates, acquisitions and disposals of businesses and working days.

Sonic said that its base business has become increasingly resilient to impacts of pandemic waves and it benefits from the essential nature of its services, as well as geographical and business diversification. Management said that the underlying growth drivers for healthcare services remain unchanged.

Summary thoughts about the Sonic share price

Sonic has done well to provide the vast levels of COVID testing and other services that it has over the last couple of years.

I think it’s a leading blue chip ASX share because of its steady growth with its core business. I also believe that COVID testing has been and could be around longer than some investors thought, generating more profit for Sonic and allowing it to use some of the profit to buy useful bolt-on businesses.

Sonic is also one of the more reliable ASX dividend shares in my opinion, so it’s on my income watchlist.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.
Skip to content